A groundbreaking study led by researchers at the University of Oxford aims to enhance prostate cancer treatment decisions using artificial intelligence (AI). Funded by Prostate Cancer UK with a £1.9 million grant, the Vanguard Path study will evaluate the ArteraAI Prostate Biopsy Assay’s effectiveness on biopsy samples from men already diagnosed with prostate cancer. This innovative technology seeks to improve accuracy in assessing cancer aggressiveness, potentially reducing unnecessary invasive treatments like surgery and radiotherapy. The study will initially test the AI tool’s predictions against real-world patient outcomes before being rolled out in clinics at three NHS sites: North Bristol NHS Trust, Oxford University Hospitals NHS Foundation Trust, and NHS Greater Glasgow and Clyde. With prostate cancer being the most common cancer in males, the use of AI could significantly personalize patient care and optimize treatment plans, ensuring better outcomes for men diagnosed with this prevalent disease.
Source link
Share
Read more